Document is current
Any future updates will be listed below
-
Authors
Antonucci, Laura
Li, Na
Duran, Angeles https://orcid.org/0000-0001-9576-0587
Cobo, Isidoro
Nicoletti, Chiara https://orcid.org/0000-0002-0872-6506
Watari, Kosuke https://orcid.org/0000-0003-0260-2323
Nandi, Shuvro Prokash https://orcid.org/0000-0003-4855-4697
Zhu, Feng
Zhao, Yongmei https://orcid.org/0000-0003-0800-4658
Riahi, Irene
Tsuda, Motoyuki
Shah, Vidhi M.
Morgan, Terry
Waugh, Trent
Caputo, Luca https://orcid.org/0000-0002-1697-9968
Liu, Yuan
Rundberg Nilsson, Alexandra https://orcid.org/0000-0002-7492-4164
Xian, Hongxu
Todoric, Jelena
Gu, Li https://orcid.org/0000-0001-5812-9024
Sanchez-Lopez, Elsa
Eibl, Guido
Vucic, Emily A.
Krawczyk, Michal
Xu, Qianlan
Lowy, Andrew M.
Hatzivassiliou, Georgia
Roose-Girma, Merone
Skowronska-Krawczyk, Dorota https://orcid.org/0000-0002-5758-4225
Scott, David A. https://orcid.org/0000-0002-8668-2449
Bar-Sagi, Dafna
Tamayo, Pablo
Wu, Ying
Sears, Rosalie C. https://orcid.org/0000-0003-1558-2413
Glass, Christopher K.
Alexandrov, Ludmil B. https://orcid.org/0000-0003-3596-4515
Puri, Pier Lorenzo
Dawson, David W.
Hu, Yinling https://orcid.org/0000-0002-4795-8537
Diaz-Meco, Maria T. https://orcid.org/0000-0003-0147-0998
Moscat, Jorge https://orcid.org/0000-0002-9442-3834
Karin, Michael https://orcid.org/0000-0002-2758-6473
- License Information
-
More Information
Article History
Received: 8 September 2023
Accepted: 20 May 2025
First Online: 30 June 2025
Competing interests
: G.H. and M.G. are employees of Genentech/Roche and hold company shares. M. Karin is a founder and scientific advisory board member of Elgia Therapeutics and has received research support from Merck, Jenssen and Gossamer Bio. L.B.A is a compensated consultant and has equity interest in io9 and Genome Insight and his spouse is an employee of Biotheranostics. L.B.A. is also an inventor of US patent 10,776,718 for source identification by non-negative matrix factorization. L.B.A. declares US provisional applications 63/289,601, 63/269,033, 63/483,237, 63/366,392 and 63/367,846. L.B.A. and S.P.N. also declare US provisional applications 63/412,835 and 63/492,348. R.C.S. is a consultant for Larkspur Biosciences and member of the scientific advisory board of RAPPTA Therapeutics and has received sponsored research support from Cardiff Oncology, AstraZeneca Partner of Choice grant award. The remaining authors declare no competing interests.
